BUSINESS WIRE; Wednesday, February 18, 1998
During the past two years, DynaGen has evaluated ImmuDyn in other conditions such as immune thrombocytopenic purpura (ITP), and autoimmune disease in which platelets are destroyed by the body's own immune system. The results of ITP human trials are equally encouraging. DynaGen is focusing its research efforts on ImmuDyn in the treatment of ITP, for which it has obtained orphan drug status from the FDA. DynaGen has formed a subsidiary, Apex Pharmaceuticals Inc., which will be independently funded to further develop and commercialize ImmuDyn.
"This patent will secure for DynaGen a strong proprietary foundation in the HIV arena for our ImmuDyn product," said Michael Sorell, M.D., director of DynaGen. "Although our initial focus is for the use of ImmuDyn in ITP, we have plans to pursue its application in other immune function disorders including HIV," he added.
DynaGen has filed patent applications for ImmuDyn for the treatment of ITP as well as for neutropenia associated with cancer chemotherapy.
DynaGen Inc. is a healthcare company founded in 1988. DynaGen's other major business activities include the BioLocator(TM) technology for the efficient and accurate localization and tracking of breast tumors, and the development of its multisource pharmaceutical business through its two subsidiaries, Able Laboratories, Inc. of South Plainfield, N.J., which manufactures tablets and suppositories, and Superior Pharmaceutical Company of Cincinnati, Ohio, a distributor of generic drugs with annual revenues in excess of $25 million.
-0-
Any statements which are not historical facts contained in this press release are forward-looking statements that involve risks and uncertainties. Please refer to the risk factors identified in the company's recent report on Form 10-K, including those relating to commercialization of products and the company's limited manufacturing and marketing experience. There can be no assurance that the anticipated benefits from the issuance of such a patent will be realized.
--30--ls/bos*
CONTACT: LBI Group Inc. Paul Lovito 800/913-9767 or Martin E. Janis & Co. Inc. Wayne Schumacher 312/943-1100
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
980218
BW980210
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .